Results 321 to 330 of about 1,088,486 (375)

The Impact of Triptorelin on Hormone Levels in Human and Its Metabolite Confirmation Using Liquid Chromatography–Ion Trap/Time‐of‐Flight Mass Spectrometry (LC/MS‐IT‐TOF) and Liquid Chromatography–Orbitrap (LC‐Orbitrap) for Doping Control Analysis

Drug Testing and Analysis, EarlyView.
Triptorelin (5–10) confirmation using LC/MS‐IT‐TOF and LC‐Orbitrap can be used as evidence of triptorelin abuse in doping control. ABSTRACT Triptorelin, a synthetic gonadotrophin‐releasing hormone (GnRH), is mainly used in the clinical treatment of prostate cancer.
Navaporn Saardpun, Cholsittapan Asawesna, Seksun Kaewklam, Premsant Sangkhum, Wisoot Kongchareonsombat, Thanit Kusamran, Darawan Pinthong   +6 more
wiley   +1 more source

Expression and Characterization of Alkaline Phosphatase from Cobetia amphilecti KMM 296 in Transiently Transformed Tobacco Leaves and Transgenic Calli. [PDF]

Plants (Basel)
Adedibu PA, Noskova YA, Yugay YA, Ovsiannikova DM, Vasyutkina EA, Kudinova OD, Grigorchuk VP, Shkryl YN, Tekutyeva LA, Balabanova LA.   +9 more
europepmc   +1 more source

Pss knockdown in the midgut causes growth retardation in Drosophila similar to that in human LMHD

Developmental Dynamics, EarlyView.
Abstract Background Phosphatidylserine synthase (PSS), localized in the mitochondrial membrane, synthesizes phosphatidylserine. In humans, mutations in Pss lead to Lenz–Majewski hyperostotic dwarfism, a disorder affecting growth and development. The effects of Pss mutations on the growth of Drosophila melanogaster are not fully known. Hence, this study
Kwan‐Young Kim, You‐Lim Hwang, Sunwoo Yeom, Seung‐Hae Kwon, Sang‐Hak Jeon   +4 more
wiley   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Comparison of serum calcium, magnesium, phosphate, alkaline phosphatase, and vitamin D levels in children consuming reverse osmosis, non reverse osmosis, and high fluoride drinking water. [PDF]

Sci Rep
Thippeswamy HM, Shanbhog R, Kumar MN, Prashanth SN, Smitha P.   +4 more
europepmc   +1 more source

METAB‐HTX: prospective, longitudinal cohort study evaluating cardiac and systemic metabolism after heart transplantation

ESC Heart Failure, EarlyView.
The METAB‐HTX trial is a prospective cohort study, evaluating cardiac and systemic metabolism among heart transplant recipients. Myocardial function, energetic and metabolism, allograft vasculopathy, allograft rejection, glucometabolism, lipometabolism, liver‐ and kidney function, leucocyte signatures and thromboinflammation will be evaluated ...
Amin Polzin, Daniel Scheiber, Fabian Voss, Jean Haurand, Elric Zweck, Daniel Oehler, Oliver Maier, Mareike Cramer, Maximilian Spieker, Constanze Moos, Ursala Tokhi, David Naguib, Philipp Mourikis, Marcel Benkhoff, Robert Wagner, Michael Roden, Heinz‐Peter Schultheiss, Sascha Dietrich, Hug Aubin, Udo Boeken, Artur Lichtenberg, Malte Kelm   +21 more
wiley   +1 more source

Relevance of residual tricuspid regurgitation for right ventricular reverse remodelling after tricuspid valve intervention in patients with severe tricuspid regurgitation and right‐sided heart failure

European Journal of Heart Failure, EarlyView.
Right ventricular reverse remodelling after transcatheter tricuspid valve intervention (TTVI). Optimal tricuspid regurgitation (TR) reduction is critical for right ventricular reverse remodelling. CMR, cardiac magnetic resonance; echo, echocardiography; RV EDV, right ventricular end‐diastolic volume. Abstract Aims Right ventricular reverse remodelling (
Ludwig T. Weckbach, Lukas Stolz, Philipp M. Doldi, Hannah Glaser, Cecilia Ennin, Michael Kothieringer, Thomas J. Stocker, Michael Näbauer, Mohammad Kassar, Sara Bombace, Karl‐Patrik Kresoja, Philipp Lurz, Fabien Praz, Holger Thiele, Volker Rudolph, Steffen Massberg, Jörg Hausleiter   +16 more
wiley   +1 more source

Visualizing the Cellular and Subcellular Distribution of Fms-like Tyrosine Kinase 3 (Flt3) and Other Neuronal Proteins Using Alkaline Phosphatase (AP) Immunolabeling. [PDF]

Int J Mol Sci
Yin Y, He KZ, Kirby J, Haque IA, Tang X.
europepmc   +1 more source

The transcriptional profile of iron deficiency in patients with heart failure: Heme‐sparing and reduced immune processes

European Journal of Heart Failure, EarlyView.
The analysis workflow, findings and potential clinical consequences of iron deficiency in heart failure (HF). From 881 patients with worsening HF, whole blood transcriptome was analysed using the Affymetrix Human Transcriptome Array (HTA) 2.0. Subjects were stratified according to their transferrin saturation (TSAT) levels as iron‐deficient (TSAT <20%)
Niels Grote Beverborg, Ridha I.S. Alnuwaysir, George Markousis‐Mavrogenis, Martijn F. Hoes, Haye H. van der Wal, Simon P.R. Romaine, Mintu Nath, Andrea Koekoemoer, John G.F. Cleland, Chim C. Lang, Stefan D. Anker, Kenneth Dickstein, Marco Metra, Leong L. Ng, Dirk J. van Veldhuisen, Adriaan A. Voors, Nilesh J. Samani, Peter van der Meer   +17 more
wiley   +1 more source

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +18 more
wiley   +1 more source